CAPR Stock Risk & Deep Value Analysis
Capricor Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CAPR Stock
We analyzed Capricor Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CAPR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is CAPR Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Low
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Low
What Are the Red Flags for CAPR?
- ⚠
Slower-than-expected patient uptake or commercialization ramp-up for CAP-1002
- ⚠
Unexpected manufacturing or supply chain issues impacting product availability
- ⚠
Emergence of a superior competitive therapy for DMD, especially in non-ambulatory patients
- ⚠
Negative safety signals or post-marketing surveillance reports for CAP-1002
Unlock CAPR Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Capricor Therapeutics Inc (CAPR) Do?
Market Cap
$1.18B
Sector
Healthcare
Industry
Biotechnology
Employees
160
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Visit Capricor Therapeutics Inc WebsiteIs CAPR Stock Undervalued?
Unlock the full AI analysis for CAPR
Get the complete DVR score, risk analysis, and more
Does CAPR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is primarily driven by regulatory exclusivity and the established clinical efficacy of CAP-1002. The complexity of developing and manufacturing a unique cell therapy creates high barriers to entry, making it difficult for competitors to replicate quickly. As CAP-1002 becomes an established standard of care for a specific patient population, physician familiarity and patient response will create switching costs.
Moat Erosion Risks
- •Loss of regulatory exclusivity and subsequent generic/biosimilar competition
- •Emergence of significantly more effective or broadly applicable gene therapies
- •Manufacturing scale-up challenges or cost inefficiencies that erode profitability
- •Slow market adoption due to logistical or reimbursement hurdles
CAPR Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive CAPR Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Call (early-March 2026) with initial commercialization commentary
- •Q1 2026 Earnings Report (early-May 2026) with first reported CAP-1002 net sales
- •Updates on payer coverage and reimbursement for CAP-1002
Medium-Term (6-18 months)
- •Data from ongoing open-label extension studies for CAP-1002
- •Initiation of pivotal clinical trial for ambulatory DMD patients (label expansion)
- •Key opinion leader (KOL) events and presentations on CAP-1002 clinical efficacy
Long-Term (18+ months)
- •Potential regulatory approval and launch for ambulatory DMD indication
- •Expansion of CAP-1002 into key international markets (e.g., Europe, Japan)
- •Exploration of CAP-1002 or next-gen CDCs for other therapeutic indications
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CAPR?
- ✓
Consistent acceleration in CAP-1002 patient starts and net sales each quarter
- ✓
Positive and rapid progress in securing broad payer coverage and favorable reimbursement terms
- ✓
Initiation and positive early data from clinical trials for ambulatory DMD or other indications
- ✓
Strong cash management and sustained access to non-dilutive or minimally dilutive capital
Bull Case Analysis
See what could go right with Premium
Compare CAPR to Similar Stocks
See how Capricor Therapeutics Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CAPR (Capricor Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
